Plant Terpenoids in Combination with Conventional Therapeutics in Colorectal Cancer: A Promising Option.

IF 4.7 2区 医学 Q1 ONCOLOGY
Chengu Niu, Jing Zhang, Patrick Rd I Okolo
{"title":"Plant Terpenoids in Combination with Conventional Therapeutics in Colorectal Cancer: A Promising Option.","authors":"Chengu Niu, Jing Zhang, Patrick Rd I Okolo","doi":"10.1007/s11912-025-01674-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Colorectal cancer accounts for approximately 10% of cancer-related mortality in Western countries. The plant-derived terpenoids represent the largest and most diverse class of natural products which possess potent anti-cancer properties in various tumor types. Combination therapy interacts with multiple targets in the molecular networks of colorectal cancer and may achieve synergistic or additive efficacy but reduce adverse side effects. The purpose of this review, mainly based on available preclinical data, is to summarize various plant terpenoids as potential sensitizers to conventional colorectal cancer therapies, along with the challenges and opportunities of these combinations in the clinical application for colorectal cancer treatment.</p><p><strong>Recent findings: </strong>A total of 33 relevant articles were considered for review. This review provided a comprehensive overview of the current state of combining plant terpenoids with conventional therapeutics for colorectal cancer treatment, and discussed the associated therapeutic challenges and opportunities for successfully translating the preclinical findings into clinical settings.. We concluded that plant terpenoids as potential adjuvants potentiate the antitumor efficacy of conventional colorectal cancer therapies by inducing apoptosis, reducing senescence, and inhibiting angiogenesis, metastasis, and inflammation through multiple pathways. Hopefully, the knowledge gained from this review will shape future research directions in this field.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01674-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Colorectal cancer accounts for approximately 10% of cancer-related mortality in Western countries. The plant-derived terpenoids represent the largest and most diverse class of natural products which possess potent anti-cancer properties in various tumor types. Combination therapy interacts with multiple targets in the molecular networks of colorectal cancer and may achieve synergistic or additive efficacy but reduce adverse side effects. The purpose of this review, mainly based on available preclinical data, is to summarize various plant terpenoids as potential sensitizers to conventional colorectal cancer therapies, along with the challenges and opportunities of these combinations in the clinical application for colorectal cancer treatment.

Recent findings: A total of 33 relevant articles were considered for review. This review provided a comprehensive overview of the current state of combining plant terpenoids with conventional therapeutics for colorectal cancer treatment, and discussed the associated therapeutic challenges and opportunities for successfully translating the preclinical findings into clinical settings.. We concluded that plant terpenoids as potential adjuvants potentiate the antitumor efficacy of conventional colorectal cancer therapies by inducing apoptosis, reducing senescence, and inhibiting angiogenesis, metastasis, and inflammation through multiple pathways. Hopefully, the knowledge gained from this review will shape future research directions in this field.

植物萜类药物联合常规疗法治疗结直肠癌:一个有希望的选择。
综述目的:在西方国家,结直肠癌约占癌症相关死亡率的10%。植物源性萜类化合物是种类最多、种类最多的一类天然产物,对各种肿瘤具有有效的抗癌作用。联合治疗与结直肠癌分子网络中的多个靶点相互作用,可能达到协同或附加效果,但减少不良副作用。本综述主要基于现有的临床前数据,旨在总结各种植物萜类化合物作为常规结直肠癌治疗的潜在增敏剂,以及这些组合在结直肠癌治疗中的临床应用所面临的挑战和机遇。最近的发现:总共考虑了33篇相关文章进行审查。本文综述了植物萜类化合物与常规治疗药物联合用于结直肠癌治疗的现状,并讨论了将临床前研究结果成功转化为临床环境的相关治疗挑战和机遇。我们得出结论,植物萜类化合物作为潜在的佐剂,通过多种途径诱导细胞凋亡、减少衰老、抑制血管生成、转移和炎症,增强了传统结直肠癌治疗的抗肿瘤功效。希望从本文中获得的知识将塑造该领域未来的研究方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.50
自引率
0.00%
发文量
187
审稿时长
6-12 weeks
期刊介绍: This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信